As the Gestational Diabetes Mellitus (GDM) Venture Leader of the Disease Interception Accelerator (DIA), Gabriele Ronnett is responsible for driving GDM interception efforts within the DIA. She and her team work closely with the Type 2 Diabetes Disease Area Stronghold (DAS) within the Cardiovascular & Metabolism (CVM) Therapeutic Area (TA) at Janssen Research & Development (R&D) to ensure continuity in scientific and commercial learnings.

Gabriele joined Janssen R&D two years ago, serving as early Compound Development Team Leader for several programs within the CVM TA. Prior to her roles at Janssen, she served as the Founding Director for the Center for Metabolism and Obesity Research (CMOR) and the Center for Resources Integrative Biology (CRIB) at The Johns Hopkins University School of Medicine. Gabriele also served as an Adjunct Professor at the Daegu Gyeongbuk Institute of Science and Technology (DGIST) in the Republic of Korea, where she founded and headed the Department of Brain Sciences, the first of its kind in Korea.

A recipient of various industry honors, Gabriele received a National Institutes of Health (NIH) Medical Scientist Training Program (MSTP) award, the Michael Shanoff Prize from The Johns Hopkins University, a Shannon Award from the NIH and a McKnight Scholars Award from The McKnight Endowment Fund for Neuroscience.

Gabriele received her Bachelor of Arts from The Johns Hopkins University and her M.D. and Ph.D. from The Johns Hopkins University School of Medicine. She performed her internal medicine training through the Osler Medical Service and her residency in the Department of Neurology at The Johns Hopkins Hospital, where she served as Chief Resident.